Lih-Chu Chiou1,2,3, Hsin-Jung Lee1, Margot Ernst4, Wei-Jan Huang5, Jui-Feng Chou1, Hon-Lie Chen1, Akihiro Mouri6,7, Liang-Chieh Chen5, Marco Treven4, Takayoshi Mamiya6, Pi-Chuan Fan8, Daniel E Knutson9, Chris Witzigmann9, James Cook9, Werner Sieghart4, Toshitaka Nabeshima6,7,10. 1. Graduate Institute of Pharmacology, National Taiwan University, Taipei, Taiwan 2. Graduate Institute of Brain and Mind Sciences, National TaiwanUniversity, Taipei, Taiwan 3. Graduate Institute of Acupuncture Science, Taichung, Taiwan 4. Center for Brain Research, Department of Molecular Neurosciences, Medical University Vienna, Vienna, Austria 5. Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan 6. Department of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan 7. Advanced Diagnostic System Research Laboratory, Graduate School of Health Sciences, Fujita Health University, Toyoake, Japan 8. Department of Pediatrics, College of Medicine, National Taiwan University, Taipei, Taiwan 9. Department of Chemistry and Biochemistry, University of Wisconsin – Milwaukee, Milwaukee, WI, USA 10. Aino University, Ibaraki, Japan
Abstract
BACKGROUND AND PURPOSE: The pathophysiological role of α6 -subunit-containing GABAA receptors, which are mainly expressed in cerebellar granule cells, remains unclear. Recently, we demonstrated that hispidulin, a flavonoid isolated from a local herb that remitted a patient's intractable motor tics, attenuated methamphetamine-induced hyperlocomotion in mice as a positive allosteric modulator (PAM) of cerebellar α6 GABAA receptors. Here, using hispidulin and a selective α6 GABAA receptor PAM, the pyrazoloquinolinone Compound 6, we revealed an unprecedented role of cerebellar α6 GABAA receptors in disrupted prepulse inhibition of the startle response (PPI), which reflects sensorimotor gating deficits manifested in several neuropsychiatric disorders. EXPERIMENTAL APPROACH: PPI disruptions were induced by methamphetamine and NMDA receptor antagonists in mice. Effects of the tested compounds were measured in Xenopus oocytes expressing recombinant α6 β3 γ2S GABAA receptors. KEY RESULTS: Hispidulin given i.p. or by bilateral intracerebellar (i.cb.) injection rescued PPI disruptions induced by methamphetamine, ketamine, MK-801 and phencyclidine. Intracerebellar effects of hispidulin were mimicked by Ro15-4513 and loreclezole (two α6 GABAA receptor PAMs), but not by diazepam (an α6 GABAA receptor-inactive benzodiazepine) and were antagonized by furosemide (i.cb.), an α6 GABAA receptor antagonist. Importantly, Compound 6 (i.p.) also rescued methamphetamine-induced PPI disruption, an effect prevented by furosemide (i.cb.). Both hispidulin and Compound 6 potentiated α6 β3 γ2S GABAA receptor-mediated GABA currents. CONCLUSIONS AND IMPLICATIONS: Positive allosteric modulation of cerebellar α6 GABAA receptors rescued disrupted PPI by attenuating granule cell activity. α6 GABAA receptor-selective PAMs are potential medicines for treating sensorimotor gating deficits in neuropsychiatric disorders. A mechanistic hypothesis is based on evidence for cerebellar contributions to cognitive functioning including sensorimotor gating.
BACKGROUND AND PURPOSE: The pathophysiological role of α6 -subunit-containing GABAA receptors, which are mainly expressed in cerebellar granule cells, remains unclear. Recently, we demonstrated that hispidulin, a flavonoid isolated from a local herb that remitted a patient's intractable motor tics, attenuated methamphetamine-induced hyperlocomotion in mice as a positive allosteric modulator (PAM) of cerebellar α6 GABAA receptors. Here, using hispidulin and a selective α6 GABAA receptor PAM, the pyrazoloquinolinone Compound 6, we revealed an unprecedented role of cerebellar α6 GABAA receptors in disrupted prepulse inhibition of the startle response (PPI), which reflects sensorimotor gating deficits manifested in several neuropsychiatric disorders. EXPERIMENTAL APPROACH: PPI disruptions were induced by methamphetamine and NMDA receptor antagonists in mice. Effects of the tested compounds were measured in Xenopus oocytes expressing recombinant α6 β3 γ2S GABAA receptors. KEY RESULTS:Hispidulin given i.p. or by bilateral intracerebellar (i.cb.) injection rescued PPI disruptions induced by methamphetamine, ketamine, MK-801 and phencyclidine. Intracerebellar effects of hispidulin were mimicked by Ro15-4513 and loreclezole (two α6 GABAA receptor PAMs), but not by diazepam (an α6 GABAA receptor-inactive benzodiazepine) and were antagonized by furosemide (i.cb.), an α6 GABAA receptor antagonist. Importantly, Compound 6 (i.p.) also rescued methamphetamine-induced PPI disruption, an effect prevented by furosemide (i.cb.). Both hispidulin and Compound 6 potentiated α6 β3 γ2S GABAA receptor-mediated GABA currents. CONCLUSIONS AND IMPLICATIONS: Positive allosteric modulation of cerebellar α6 GABAA receptors rescued disrupted PPI by attenuating granule cell activity. α6 GABAA receptor-selective PAMs are potential medicines for treating sensorimotor gating deficits in neuropsychiatric disorders. A mechanistic hypothesis is based on evidence for cerebellar contributions to cognitive functioning including sensorimotor gating.
Authors: Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath Journal: Br J Pharmacol Date: 2015-07 Impact factor: 8.739
Authors: K L Hadingham; E M Garrett; K A Wafford; C Bain; R P Heavens; D J Sirinathsinghji; P J Whiting Journal: Mol Pharmacol Date: 1996-02 Impact factor: 4.436
Authors: Daniele Caligiore; Giovanni Pezzulo; Gianluca Baldassarre; Andreea C Bostan; Peter L Strick; Kenji Doya; Rick C Helmich; Michiel Dirkx; James Houk; Henrik Jörntell; Angel Lago-Rodriguez; Joseph M Galea; R Chris Miall; Traian Popa; Asha Kishore; Paul F M J Verschure; Riccardo Zucca; Ivan Herreros Journal: Cerebellum Date: 2017-02 Impact factor: 3.847
Authors: Pi-Chuan Fan; Tzu-Hsuan Lai; Chia Chun Hor; Ming Tatt Lee; Pokai Huang; Werner Sieghart; Margot Ernst; Daniel E Knutson; James Cook; Lih-Chu Chiou Journal: Neuropharmacology Date: 2018-07-21 Impact factor: 5.250
Authors: Jelena R Mitrović; Branka Divović; Daniel E Knutson; Jelena B Đoković; Predrag J Vulić; Danijela V Randjelović; Vladimir D Dobričić; Bojan R Čalija; James M Cook; Miroslav M Savić; Snežana D Savić Journal: Eur J Pharm Sci Date: 2020-06-18 Impact factor: 5.112
Authors: Roberto Cadeddu; Daniel E Knutson; Laura J Mosher; Stefanos Loizou; Karen Odeh; Janet L Fisher; James M Cook; Marco Bortolato Journal: Biomolecules Date: 2021-01-28
Authors: Hung-Ruei Tzeng; Ming Tatt Lee; Pi-Chuan Fan; Daniel E Knutson; Tzu-Hsuan Lai; Werner Sieghart; James Cook; Lih-Chu Chiou Journal: Neurotherapeutics Date: 2020-10-27 Impact factor: 7.620